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conclusion, gilteritinib was well tolerated and demonstrated antileukemic activity in a Japanese R/R AML population.
K E Y W O R D S
acute myeloid leukemia, bone marrow, fms-like tyrosine kinase 3, hematopoiesis, mutation
| INTRODUCTION
Fms-like tyrosine kinase 3 (FLT3), expressed on the surface of hematopoietic progenitor cells, plays a critical role in the proliferation, survival and differentiation of multipotent stem cells. 1 Activating mutations in the FLT3 gene occur in approximately 30% of patients with acute myeloid leukemia (AML) and confer a poor prognosis. [2] [3] [4] Two unique activating FLT3 mutations occur at specific hotspots: internal tandem duplications (FLT3-ITD) in the juxtamembrane domain and secondary point mutations in the tyrosine kinase domain (FLT3-TKD), most commonly in codon D835. 5, 6 As such, FLT3-ITD mutations are strong predictors of rapid relapse and short overall survival (OS), whereas secondary FLT3-TKD point mutations may confer resistance to FLT3 inhibitors. 4, [7] [8] [9] Gilteritinib is a highly specific, potent FLT3/AXL inhibitor with demonstrated activity against FLT3 receptors containing FLT3-ITD and FLT3-TKD D835 mutations. 10, 11 Preclinical studies have demonstrated that gilteritinib is a robust inhibitor of FLT3 and AXL, as well as anaplastic lymphoma kinase and leukocyte receptor tyrosine kinase. 11 In leukemic cells, gilteritinib strongly inhibited FLT3 receptors expressing FLT3-ITD and FLT3-TKD D835 mutations, and was a weak inhibitor of FLT3 receptors expressing F691 gatekeeper mutations. 10 AXL, an oncogenic tyrosine kinase that promotes FLT3 activation and may be involved in FLT3 inhibitor resistance, is often overexpressed in patients with AML. 12, 13 Because gilteritinib also blocks AXL, which has been shown to suppress the growth of FLT3-ITD AML and decrease tumor size, this dual inhibition mechanism may enhance the benefit of gilteritinib in AML. 12, 14 Furthermore, gilteritinib has a minimal inhibitory effect on c-Kit, suggesting a lower risk of myelosuppression compared with other tyrosine kinase inhibitors. 11, 15 In a recently published phase 1/2 dose-escalation/ expansion study of once-daily oral gilteritinib in patients with relapsed/refractory (R/R) AML from the USA, Germany and Italy, gilteritinib was well tolerated with a maximum tolerated dose (MTD) of 300 mg/d. 16 Gilteritinib doses ≥80 mg/d were associated with consistent and potent FLT3 inhibition and strong antileukemic response, with an overall response rate (ORR) of 52% and a median OS duration of 31 weeks. 16 We conducted a multicenter open-label phase 1 dose-escalation study of gilteritinib in Japanese patients aged ≥18 years with R/R AML. The key objective was to assess the safety and tolerability of gilteritinib with respect to the MTD and determination of the recommended dose (RD) for subsequent studies. Secondary objectives were to evaluate the antileukemic activity and the pharmacokinetic (PK) profile of gilteritinib. This trial is registered as ClinicalTrials.gov identifier NCT02181660.
| MATERIALS AND METHODS

| Study design and participants
This was an open-label phase 1 dose-escalation study conducted 
| Procedures
Patients were enrolled into 1 of 6 dose-escalation cohorts: 20, 40, 80, 120, 200, and 300 mg. Initially, at least 1 patient was to be enrolled at a starting dose of 20 mg/d, with at least 3 patients enrolled at each subsequent dose level using the Bayesian continualreassessment method (CRM; Figure S1 ).
17
Patients received an initial dose of oral gilteritinib followed by a 2-day observation period (Cycle 0); beginning on Cycle 1 Day 1, patients followed a repeated dose protocol, receiving oral gilteritinib once a day in a 28-day cycle until a discontinuation criterion was met ( Figure 1 ). Discontinuation criteria included pregnancy (patient or patient's partner), withdrawal of consent, unacceptable adverse events (AEs), failure to achieve partial remission (PR), complete remission (CR), complete remission with incomplete platelet recovery (CRp) or complete remission with incomplete hematologic recovery (CRi) after Cycle 2, and investigator determination that continuation of study treatment would be detrimental to the patient.
Dose-limiting toxicities (DLTs) were determined based on safety results from Cycles 0 and 1 in each dose cohort. A DLT was defined as any grade ≥3 nonhematological or extramedullary toxicity that occurred during Cycles 0 or 1 and that was considered by the investigator to be possibly, probably or definitely related to the study drug. Prolonged myelosuppression was considered to be a DLT.
Exceptions to the definition of a DLT are noted in Appendix S1.
At the end of Cycle 1 and subsequent cycles, dose escalation was permitted if: (i) no DLT had occurred; (ii) gilteritinib was determined to be tolerable at the next dose level and no dose reductions occurred; or (iii) the patient had requested the dose escalation and escalation was not expected (in the investigator's opinion) to result in any safety concerns. Dose escalation was also permitted if patients did not achieve CR, CRp or CRi after completion of Cycle 1.
The MTD and RD were established on the basis of the posterior mean of the DLT rate using the Bayesian CRM and investigator assessment. Criteria for dose reductions and interruptions, treatment discontinuation and MTD determination are outlined in Appendix S1.
| Assessments and outcomes
Safety and tolerability were assessed by local site-specific monitoring (Table S1 ). 18 Duration of response was 
| Statistical analysis
Sample size was based on a maximum of 6 DLT evaluable subjects 
, n
Prior AML therapy, n dose group who had completed 17 cycles of treatment was excluded from exposure analysis due to compliance issues, given that the actual dates of missed doses were unknown.
| Safety and tolerability of gilteritinib
Of the 24 patients in the SAF, a total of 3 patients experienced [91.7%]) experienced at least 1 treatment-related AE ( Table 2 ). As presented in Table 3 , the most common AEs (occurring in ≥20% of patients) were elevated liver enzymes (ie, alanine aminotransferase, 
| PK profile of gilteritinib
Mean plasma concentration-time curves for gilteritinib after single and multiple doses are presented in Figure 2 . Median t max was reached between 3 and 7 hours after administration of single or multiple doses of gilteritinib (Tables S2 and S3 ). Single-dose and multiple-dose gilteritinib exposure increased in a dose-proportional manner (Table S4) and ≤13.1% after multiple doses (Table S5 ).
| DISCUSSION
This is the first clinical study of a FLT3 inhibitor in a Japanese R/R AML population. Overall, results from this phase 1 dose-escalation study of gilteritinib demonstrate that gilteritinib was well tolerated CI, confidence interval; CR, complete remission; CRc, composite complete remission (CR plus CRp plus CRi); CRi, complete remission with incomplete hematological recovery; CRp, complete remission with incomplete platelet recovery; ORR, overall response rate; PR, partial remission.
Response was defined as CRc plus PR.
a Exact 95% CI was established using the binomial distribution.
b
Of all patients in the full analysis set, data regarding FLT3 mutation status were missing for 2 patients and were invalid for 1 patient.
c FLT3 mutation status was determined by a central laboratory. 19 were higher in the JALSG AML201 study population than in the US/European AML population (6% and 4%, respectively). 2 The higher number of patients with c-Kit mutations could be attributed to the increased occurrence of core-binding factor AML in the JALSG AML201 study population. 19 Despite these potential mutational differences, the reported outcomes after treatment with gilteritinib in Japanese patients with R/R AML in the current study were generally similar to those reported in the larger phase 1/2 US/European R/R AML study population.
Several multikinase and FLT3 inhibitors have been evaluated in patients with AML. As a single agent, the multikinase inhibitor midostaurin reduced peripheral blast counts in both patients with mutated and wild-type FLT3 AML; 20 however, bone marrow blast reductions were limited, clinical response duration was brief (50-56 days) and CR was not achieved. 20 In patients aged <60 years, the 3-year event-free survival rate after treatment with sorafenib plus intensive chemotherapy (40%) was greater than that observed in the placebo arm (22%). However, no improvement in OS and a higher incidence of grade ≥3 AEs was observed in the sorafenib arm. 21 In patients aged >60 years, sorafenib plus intensive chemotherapy did not improve CR rates or event-free survival and OS. 22 Of the FLT3 inhibitors in development, quizartinib is associated with high response rates in patients with R/R AML; however, durable survival necessitated allogeneic HSCT. 23 Treatment resistance, attributable to the development of treatment-emergent FLT3-TKD mutations, was frequently observed in nontransplanted patients. 24 Moreover, prolongation of the QTc interval was observed at doses of 200 and 300 mg, 25 and inhibition of c-Kit by quizartinib was associated with myelosuppression. 15, 26 In patients with FLT3 mutationpositive R/R AML, crenolanib showed strong antileukemic activity;
however, CR/CRi rates were low; nausea, vomiting and hepatotoxic AEs were frequently observed. 27, 28 In this study, elevated liver enzyme levels observed in one-third of patients with R/R AML were associated with gilteritinib therapy;
however, all cases were less than grade 3 in severity. Hepatotoxicity was also associated with sorafenib and crenolanib therapy in patients with FLT3 mutation-positive AML. 28, 29 Among other common AEs related to gilteritinib therapy reported in the current study, elevated blood creatine phosphate levels and elevated blood lactate dehydrogenase levels were identified as DLTs in only 2 patients, both of whom had received gilteritinib doses of 300 mg/d.
Furthermore, the occurrence of a possible treatment-related prolongation of the QTcF interval was observed in only 1 patient (4.2%) in the 40 mg/d dose cohort.
As with other small-scale nonrandomized nonblinded phase 1 studies, evaluation of gilteritinib in an ethnically homogeneous patient population restricts extrapolation of these results to the larger R/R AML population. The short follow-up period (28 days) did not allow for assessment of long-term safety, durability of response and long-term survival. Unlike the FLT3 mutation-enriched R/R AML population in the phase 1/2 study, 16 most patients (approximately 67%) in our study were FLT3 mutation negative. Despite these limitations, no significant differences in response rate, safety or PK profiles of gilteritinib were observed between our study and the phase 1/2 study. 16 Furthermore, the demonstrated activity of gilteritinib against FLT3-TKD mutations suggest a potential benefit in treatmentresistant FLT3 mutation-positive AML. 10, 11 In conclusion, gilteritinib was well tolerated and induced antileukemic responses in a Japanese R/R AML patient population that were comparable to those observed in FLT3 mutation-enriched US/ European patients with R/R AML. 16 Response rates with gilteritinib monotherapy were higher than those reported for other FLT3 inhibitors. 23, 25, 27, 28 Our data further demonstrate the utility of gilteritinib as a single agent in the treatment of R/R AML. With no currently approved treatment for FLT3 mutation-positive R/R AML in Japan, gilteritinib is a promising therapeutic agent.
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